JP2017517507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017517507A5 JP2017517507A5 JP2016568657A JP2016568657A JP2017517507A5 JP 2017517507 A5 JP2017517507 A5 JP 2017517507A5 JP 2016568657 A JP2016568657 A JP 2016568657A JP 2016568657 A JP2016568657 A JP 2016568657A JP 2017517507 A5 JP2017517507 A5 JP 2017517507A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- variable region
- chain variable
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC(*)[C@]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@@](C3)N4c5c3cccc5)c2C4=O)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC(*)[C@]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@@](C3)N4c5c3cccc5)c2C4=O)c1)S 0.000 description 14
- JSHOVKSMJRQOGY-UHFFFAOYSA-N O=C(CCCSSc1ncccc1)ON(C(CC1)=O)C1=O Chemical compound O=C(CCCSSc1ncccc1)ON(C(CC1)=O)C1=O JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 6
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N OS(C(CCSSc1ccccn1)C(ON(C(CC1)=O)C1=O)=O)(=O)=O Chemical compound OS(C(CCSSc1ccccn1)C(ON(C(CC1)=O)C1=O)=O)(=O)=O FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 description 3
- DOKWDOLZCMETIJ-ZAQUEYBZSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S DOKWDOLZCMETIJ-ZAQUEYBZSA-N 0.000 description 2
- VEVCIXHNMIPJED-MGAVHJTQSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(c(OC)c2)cc(NC[C@H](C3)N4c5c3cccc5)c2C4=O)c1)S VEVCIXHNMIPJED-MGAVHJTQSA-N 0.000 description 2
- NJFZGSDCOLQLAD-CBYVCPMDSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=CC3(C)N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCCC1)=O Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=CC3(C)N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCCC1)=O NJFZGSDCOLQLAD-CBYVCPMDSA-N 0.000 description 1
- IJZPSYGVMFYGJO-ORTKPCQYSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCC(C(NC(C)(C)C1CCCC1)=O)S(O)(=O)=O Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)cc(COc(cc(c2c3)NC[C@H](Cc4ccccc44)N4C2=O)c3OC)c1)SSCCC(C(NC(C)(C)C1CCCC1)=O)S(O)(=O)=O IJZPSYGVMFYGJO-ORTKPCQYSA-N 0.000 description 1
- OCRAJZOPOBJAEN-GCOKTQCFSA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC#CC(Cc4ccccc44)N4C2=O)c3OC)c1)S Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC#CC(Cc4ccccc44)N4C2=O)c3OC)c1)S OCRAJZOPOBJAEN-GCOKTQCFSA-N 0.000 description 1
- GQGJQCFYSSWHRF-HYNIKSJISA-N CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC[C@H](CC4=C5CCC=C4)N5C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCC1)=O Chemical compound CC(C)(CN(CCOCCOCCOC)c1cc(COc(c(OC)c2)cc(NC([C@H]3N4c5ccccc5C3)S(O)(=O)=O)c2C4=O)cc(COc(cc(c2c3)NC[C@H](CC4=C5CCC=C4)N5C2=O)c3OC)c1)SSCCCC(NC(C)(C)C1CCC1)=O GQGJQCFYSSWHRF-HYNIKSJISA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462001015P | 2014-05-20 | 2014-05-20 | |
| US62/001,015 | 2014-05-20 | ||
| US201462011456P | 2014-06-12 | 2014-06-12 | |
| US62/011,456 | 2014-06-12 | ||
| US201462075715P | 2014-11-05 | 2014-11-05 | |
| US62/075,715 | 2014-11-05 | ||
| PCT/US2015/031580 WO2015179400A2 (en) | 2014-05-20 | 2015-05-19 | Methods for characterizing and treating acute myeloid leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017517507A JP2017517507A (ja) | 2017-06-29 |
| JP2017517507A5 true JP2017517507A5 (enExample) | 2018-07-05 |
Family
ID=54554957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568657A Pending JP2017517507A (ja) | 2014-05-20 | 2015-05-19 | 急性骨髄性白血病を特徴付け、治療する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170080102A1 (enExample) |
| EP (1) | EP3145542A4 (enExample) |
| JP (1) | JP2017517507A (enExample) |
| KR (1) | KR20170004003A (enExample) |
| CN (1) | CN106456762A (enExample) |
| AU (1) | AU2015264322A1 (enExample) |
| BR (1) | BR112016026730A2 (enExample) |
| CA (1) | CA2947602A1 (enExample) |
| IL (1) | IL248555A0 (enExample) |
| MA (1) | MA39885A (enExample) |
| RU (1) | RU2016147398A (enExample) |
| SG (1) | SG11201609357PA (enExample) |
| WO (1) | WO2015179400A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| SMT202100092T1 (it) * | 2015-06-29 | 2021-03-15 | Immunogen Inc | Anticorpi anti-cd123 e loro coniugati e derivati |
| EP3469001A4 (en) * | 2016-06-09 | 2020-05-06 | Seattle Genetics, Inc. | COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS |
| RU2019114863A (ru) * | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
| WO2018183494A1 (en) * | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| JP2020519640A (ja) * | 2017-05-17 | 2020-07-02 | イミュノジェン， インコーポレイテッド | 抗ｃｄ３３イムノコンジュゲート投与計画 |
| US20190160089A1 (en) * | 2017-10-31 | 2019-05-30 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
| CN119857155A (zh) | 2017-11-29 | 2025-04-22 | 海德堡医药研究有限责任公司 | 用于耗尽cd5+细胞的组合物和方法 |
| TW202003048A (zh) * | 2018-05-15 | 2020-01-16 | 美商伊繆諾金公司 | 用抗體-藥物偶聯物及flt3抑制劑之組合治療 |
| WO2020010262A1 (en) * | 2018-07-06 | 2020-01-09 | University Of Washington | High throughput drug screening of cancer stem cells |
| WO2020051013A2 (en) * | 2018-08-24 | 2020-03-12 | The Trustees Of Columbia University In The City Of New York | Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies |
| JP7788859B2 (ja) * | 2019-06-26 | 2025-12-19 | メモリアル スローン ケタリング キャンサー センター | がんを処置するための抗ｃｄ３３抗体 |
| WO2025265055A1 (en) * | 2024-06-21 | 2025-12-26 | The Johns Hopkins University | Materials and methods for treating myeloid neoplasms |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6007814A (en) * | 1992-06-15 | 1999-12-28 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| WO2010126552A1 (en) * | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent cell-binding agent drug conjugates |
| WO2012044696A2 (en) * | 2010-09-30 | 2012-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Prediction of clinical outcome in hematological malignancies using a self-renewal expression signature |
| KR20140010076A (ko) * | 2011-02-15 | 2014-01-23 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체 |
| US20120282282A1 (en) * | 2011-04-04 | 2012-11-08 | Immunogen, Inc. | Methods for Decreasing Ocular Toxicity of Antibody Drug Conjugates |
-
2015
- 2015-05-19 KR KR1020167035135A patent/KR20170004003A/ko not_active Withdrawn
- 2015-05-19 RU RU2016147398A patent/RU2016147398A/ru not_active Application Discontinuation
- 2015-05-19 BR BR112016026730A patent/BR112016026730A2/pt not_active IP Right Cessation
- 2015-05-19 CN CN201580026480.1A patent/CN106456762A/zh active Pending
- 2015-05-19 US US15/311,632 patent/US20170080102A1/en not_active Abandoned
- 2015-05-19 JP JP2016568657A patent/JP2017517507A/ja active Pending
- 2015-05-19 MA MA039885A patent/MA39885A/fr unknown
- 2015-05-19 WO PCT/US2015/031580 patent/WO2015179400A2/en not_active Ceased
- 2015-05-19 CA CA2947602A patent/CA2947602A1/en not_active Abandoned
- 2015-05-19 SG SG11201609357PA patent/SG11201609357PA/en unknown
- 2015-05-19 EP EP15795831.5A patent/EP3145542A4/en not_active Withdrawn
- 2015-05-19 AU AU2015264322A patent/AU2015264322A1/en not_active Abandoned
-
2016
- 2016-10-27 IL IL248555A patent/IL248555A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016147398A (ru) | Способы оценивания и лечения острого миелоидного лейкоза | |
| CN110177806B (zh) | 与met结合的抗met抗体、双特异性抗原结合分子及其使用方法 | |
| AU2013355172B2 (en) | BCMA antigen binding proteins | |
| JP6877357B2 (ja) | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 | |
| ES3034582T3 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody | |
| JP5909442B2 (ja) | ヒト化ａｘｌ抗体 | |
| KR102007055B1 (ko) | Cd27l 항원 결합 단백질 | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| AU2017208554B2 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| US12371507B2 (en) | CDCP1 antibodies and antibody drug conjugates | |
| JP6527132B2 (ja) | 肝臓がんの診断及び治療のための組成物及び方法 | |
| US20140271644A1 (en) | Combination/adjuvant therapy for wt-1-positive disease | |
| JP2020502271A5 (enExample) | ||
| JP2016539083A5 (enExample) | ||
| TW200813090A (en) | Combinatorial therapy | |
| US20190194309A1 (en) | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof | |
| JP2012529281A5 (enExample) | ||
| JP2017501137A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| RS53327B (sr) | Monoklonsko antitelo na cd44, za korišćenje u lečenju karcinoma skvamoznih ćelija glave i vrata | |
| JPWO2020040245A5 (enExample) | ||
| KR20220113951A (ko) | 항-ror-2 항체 및 사용 방법 | |
| JP2024023278A (ja) | Ａｌｋ７結合タンパク質およびその使用 | |
| JP2023539493A5 (enExample) | ||
| JP2021535110A (ja) | 併用療法 |